source
- Mineralys makes money moves before looming hypertension approvalMineralys Therapeutics first drew attention in 2021 with a bold bet on a new type of hypertension drug called lorundrostat. It came with a tiny $1 million upfront fee to the medicine's originator,…Endpoints · 1mo ago↗ source
- STAT+: What the pope’s encyclical on AI means for Catholic hospitals, and all of health careIn this edition of STAT's AI Prognosis: Brittany Trang analyzes the pope's encyclical on artificial intelligence for takeaways relevant for health care.STAT · 1mo ago↗ source
- STAT+: Legend Biotech emerged as a rare market winnerNew guidance for gene therapy developers, Lilly's deal for kidney drugs, and more biotech news from The ReadoutSTAT · 1mo ago